Literature DB >> 34166994

Treatment-emergent central sleep apnea associated with non-positive airway pressure therapies in obstructive sleep apnea patients: A systematic review.

Mathieu Berger1, Geoffroy Solelhac2, Christian Horvath3, Raphael Heinzer2, Anne-Kathrin Brill3.   

Abstract

This systematic review summarizes the prevalence of treatment-emergent central sleep apnea (TECSA) occurring with therapies other than positive airway pressure (PAP) for the management of obstructive sleep apnea (OSA). We describe its natural course as well as the proposed underlying pathophysiological mechanisms and the clinical management of affected patients. A systematic search of PubMed, Embase, Web of science, and the Cochrane Library was performed until June 2020. Eighteen studies (n = 284 patients) were included. TECSA was observed in 31 patients with the use of four different medical devices (mandibular advancement device, hypoglossal nerve stimulation, tongue stabilizing device and nasal expiratory PAP) and after three different types of surgical treatments (tracheostomy, maxillofacial surgery and oro-nasal surgery). Due to the paucity of data available, it was not possible to establish a clear prevalence rate of TECSA for each alternative treatment. After the initiation of non-PAP treatments, a systematic reassessment of the treatment efficacy with follow-up sleep studies will be helpful to identify TECSA. A spontaneous resolution over time was described as well as a persistence of TECSA. In this case, treatment should focus on patients' specific underlying pathophysiology. Overall, the limited current literature suggests that this phenomenon is rare (<4%).
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Central sleep apnea; Complex sleep apnea; Obstructive sleep apnea; Treatment-emergent central sleep apnea

Year:  2021        PMID: 34166994     DOI: 10.1016/j.smrv.2021.101513

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  1 in total

1.  Hypoglossal Nerve Stimulation Therapy.

Authors:  Philipp Arens; Toni Hänsel; Yan Wang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.